Hikma Pharmaceuticals Plc
24 August 2026
Hikma Pharmaceuticals PLC
(the "Company")
LONDON, 24 August 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces it has been notified of the following transactions by Persons Discharging Managerial Responsibilities ("PDMRs") of the Company.
This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities
Said Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Said Darwazah |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
Mazen Darwazeh
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Mazen Darwazeh |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice Chairman and Deputy CEO, MENA |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
Ali Al-Husry
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Ali Al-Husry |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Non-Executive Director |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction |
Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. |
|
c) |
Price(s) and volume(s) |
Price(s): £0.00 Volume(s): 2,000,000 |
|
d) |
Aggregated information |
Aggregated volume: 2,000,000 Price: £0.00 |
|
e) |
Date of the transaction |
21 August 2026 |
|
f) |
Place of the transaction |
Amman, Jordan |
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.